These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 7793141

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Therapy of arterial occlusive diseases. The effect of bencyclan in trained patients with peripheral arterial occlusive disease (Double-blind study)].
    Battke K, Buchwalsky R, Barmeyer J, Hoffmann G, Reindell H.
    Fortschr Med; 1978 Jul 20; 96(26-27):1381-6. PubMed ID: 669532
    [No Abstract] [Full Text] [Related]

  • 23. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
    Trübestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, Horsch S, Kriessmann A, Maass U, Martin M.
    Vasa Suppl; 1989 Jul 20; 28():44-9. PubMed ID: 2692200
    [Abstract] [Full Text] [Related]

  • 24. [Hemodilution in patients with multiple morbidity and peripheral arterial occlusive disease].
    Kiesewetter H, Blume J, Jung F, Spitzer S, Bach R, Birk A, Schieffer H, Wenzel E.
    Schweiz Med Wochenschr; 1989 Dec 23; 119(51):1862-7. PubMed ID: 2481883
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The treadmill test in the assessment of peripheral arterial occlusive disease.
    Ucchino S, Nardi M, Santarelli M, Legnini M, Costantini A, Ucchino G, Napolitano AM.
    Panminerva Med; 1992 Dec 23; 34(3):120-3. PubMed ID: 1491870
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
    Lehert P, Riphagen FE, Gamand S.
    J Cardiovasc Pharmacol; 1990 Dec 23; 16 Suppl 3():S81-6. PubMed ID: 1369727
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
    Kiesewetter H, Blume J, Jung F, Spitzer S, Gerhards M, Waldhausen P, Wenzel E.
    Wien Med Wochenschr; 1989 Sep 15; 139(17):396-401. PubMed ID: 2480029
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Vasogen's immune modulation therapy (IMT) improves postischemic foot skin blood flow and transcutaneous pO(2) recovery rates in patients with advanced peripheral arterial occlusive disease.
    Edvinsson LI, Edvinsson ML, Angus Deveber G.
    Int Angiol; 2003 Jun 15; 22(2):141-7. PubMed ID: 12865879
    [Abstract] [Full Text] [Related]

  • 38. [Results of physical therapy of peripheral arterial circulatory disorders (VI). Present position of the results in the Steglitz Hospital, Berlin].
    Krause D.
    MMW Munch Med Wochenschr; 1975 Mar 14; 117(11):453-6. PubMed ID: 804623
    [Abstract] [Full Text] [Related]

  • 39. [Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].
    Branchereau A, Rouffy J.
    J Mal Vasc; 1995 Mar 14; 20(1):21-7. PubMed ID: 7745355
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.